The Ross laboratory at Stanford University is seeking a postdoc to extend recent findings on rejuvenating aged immune systems through stem cell modulation (Ross et al., Nature 2024).
The Sheltzer Lab at Stanford University is seeking a postdoctoral researcher for a cutting-edge project applying CRISPR to dissect the consequences of copy-number alterations in iPS cells.
The Kalbasi laboratory tackles questions at the intersection of immunology and cancer biology, with an emphasis on therapeutic development. Here are some selected areas of interest:
We perform translational cancer research by analyzing human tissue and blood samples with next-generation sequencing to understand the genetic underpinnings and expression signatures that determine treatment response and resistance. We use genetically engineered mouse models to validate our findings, perform mechanistic experiments, and test new therapies. Our ultimate goal is to translate our findings to the clinic to improve outcomes for patients with cancer.
Use artificial intelligence in image and biology guided radiotherapy and medical image analysis (PET/CT).
Theranostic nanoparticles for radiosensitization and medical imaging.
Novel treatment technique for ocular disease radiotherapy.
Radio-neuromodulation using focused kV x-rays.
Ultrasound parametric imaging.
The gene encoding the p53 transcription factor is the most commonly mutated gene in human cancer, yet we lack a complete understanding of how its loss promotes cancer and how to target this pathway therapeutically. My lab studies p53 in the context of two very deadly and common cancer, pancreatic cancer and lung cancer, to understand how p53 loss promotes tumor initiation and progression. We are investigating not only how p53 mutation changes tumor cells themselves but also how these changes in tumor cells alter the cells of the tumor microenvironment to promote cancer development.
My lab is an interdisciplinary group spanning medical physics and technology development, basic cancer and radiation biology, and preclinical and clinical imaging.
The two main programs are:
The overarching research goal of the Diehn lab is to develop and translate novel diagnostic assays and therapies to improve personalized treatment of cancer patients. We have a major focus on the development and application of liquid biopsy technologies for human cancers, with a particular emphasis on lung cancers and circulating tumor DNA (ctDNA). We also investigate mechanisms of treatment resistance to radiotherapy, immunotherapy, and targeted agents.
The Frock laboratory is interested in elucidating mechanisms of DNA double-stranded break (DSB) repair and chromosome translocations. We employ a high-throughput sequencing technology that identifies and maps cellular DSBs. We are interested in further developing this technology to more fully quantify the DSB repair fates from targeted DSBs. Our research disciplines are broad and cover aspects of molecular and cancer biology, bioinformatics. immunology, genome editing, and radiation biology.
An emerging hallmark of cancer is the modulation of metabolic pathways by malignant cells to promote cancer development. Dr. Jiangbin Ye’s professional interest is to investigate the causes and consequences of the abnormal metabolic phenotypes of tumor cells, with the prospect that therapeutic approaches might be developed to target these metabolic pathways to improve cancer treatment. The lab’s current goal is to explore the complex role of metabolic reprogramming in epigenetic regulations, and how cell fate and differentiation process are controlled by these epigenetic regulations.